ArticleCellular signalling2025
The role of arrestin-1 N-edge in rhodopsin binding.
Article in Cellular signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phosphorylation site topology governs the functional dynamics of arrestin recruitment to GPCRs.Research square · 2026Article
- Deceptive beauty of non-natural structures.Protein science : a publication of the Protein Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Arrestin-1, in contrast to other subtypes, demonstrates exquisite selectivity for the active phosphorylated form of its cognate receptor, rhodopsin. The loop between β-strands IX and X, termed N-edge because it is located on the distal tip of the N-domain in the folded arrestin molecule, was implicated in the binding of arrestin-1 and -2 to their cognate receptors. We performed alanine scanning and charge reversal mutagenesis of all twelve residues in this element of bovine arrestin-1. The mutants were tested for the binding to phosphorylated and unphosphorylated light-activated rhodopsin in the context of wild type and "enhanced" in terms of receptor binding C-terminally truncated arrestin-1-(1-378). The data identified two phosphate-binding lysines and seven other residues enhancing arrestin-1 preference for phosphorylated rhodopsin over unphosphorylated. We deleted three of these that are absent in the other mammalian arrestins and found that this insert is generally important for rhodopsin binding, not for enhanced selectivity. Eleven out of nineteen mutations differentially affected the binding of wild type arrestin-1 and its enhanced mutant, suggesting that the prevalent form of the complex of these two arrstin-1 variants with rhodopsin is different.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.